

Two competing statins similarly effective

By ACSH Staff — September 6, 2011

The battle of the statins has resulted in a draw, as the data from the two-year SATURN study of over 1,300 patients are in. Scientists found that AstraZeneca's Crestor (rosuvastatin) and Pfizer's Lipitor (atorvastatin) actually have comparable effects when it comes to lowering the volume of fatty deposits in the arteries of patients with coronary disease a conclusion that surprised both cardiologists and AstraZeneca.

Simply stated, says ACSH's Dr. Ruth Kava, this is good news. Now people have the choice of taking either drug without sacrificing any of the benefits.

COPYRIGHT © 1978-2016 BY THE AMERICAN COUNCIL ON SCIENCE AND HEALTH

Source URL: <https://www.acsh.org/news/2011/09/06/two-competing-statins-similarly-effective>